Introduction {#jcmm12716-sec-0001}
============

Atherosclerosis is characterized by the formation of plaques on the inner walls of arteries that threatens to become the leading cause of death worldwide *via* its sequelae of acute myocardial infarction (AMI) and stroke. Many studies show that oxidized low‐density lipoproteins (ox‐LDL) play a key role in atherogenesis. Indeed, sub‐endothelial retention of ox‐LDL is considered the initial event of atherogenesis, followed by the infiltration and activation of inflammatory cells circulating in the blood [1](#jcmm12716-bib-0001){ref-type="ref"}. Lectin‐like oxidized low‐density lipoprotein receptor‐1 (LOX‐1) is the main ox‐LDL endothelial scavenger receptor (SR) [2](#jcmm12716-bib-0002){ref-type="ref"} and the ox‐LDL/LOX‐1 interaction contributes to the triggering of endothelial dysfunction characteristic of atherosclerosis development [1](#jcmm12716-bib-0001){ref-type="ref"}. Moreover, single nucleotide polymorphisms (SNPs) in the *OLR1* gene, encoding LOX‐1, have been associated with the risk of developing AMI [3](#jcmm12716-bib-0003){ref-type="ref"}, [4](#jcmm12716-bib-0004){ref-type="ref"}.

*OLR1* ([NM_002543](NM_002543)) is subjected to alternative splicing generating two isoforms: Loxin ([NM_001172633](NM_001172633)) [5](#jcmm12716-bib-0005){ref-type="ref"} and OLR1D4 ([NM_001172632](NM_001172632)). OLR1D4 lacks exon 4, so the putative encoded protein is shorter with a distinct C‐terminus. No other data are available for this isoform. On the contrary, Loxin, the splice isoform lacking exon 5, is well known and characterized [5](#jcmm12716-bib-0005){ref-type="ref"}, [6](#jcmm12716-bib-0006){ref-type="ref"}. It encodes for a truncated receptor (LOXIN) lacking two‐thirds of LOX‐1 functional lectin‐like binding domain. LOXIN forms heterodimers with LOX‐1 reducing the cells' ability to bind ox‐LDL; when LOXIN is co‐expressed with LOX‐1, it is able to rescue cells from LOX‐1‐induced apoptosis in a dose‐dependent manner [6](#jcmm12716-bib-0006){ref-type="ref"}. Moreover, *in vivo* studies on animal models indicate that LOXIN expression induces a significant decrease in plaque coverage within the common carotid artery [7](#jcmm12716-bib-0007){ref-type="ref"}.

MicroRNAs (miRNAs) are small single‐stranded non‐coding RNAs of 18--23 nucleotides, active in the regulation of gene expression both at transcriptional and post‐transcriptional levels. MicroRNAs, in fact, can block mRNA translation through a partial bond with complementary mRNA targets or determine a complete degradation when pairing is perfectly complementary [8](#jcmm12716-bib-0008){ref-type="ref"}.

Previous studies have described interactions among *OLR1* and different miRNAs; within them, particularly interesting are hsa‐let7‐g [9](#jcmm12716-bib-0009){ref-type="ref"} and hsa‐miR‐21 [10](#jcmm12716-bib-0010){ref-type="ref"} that are expressed mainly in endothelial cells and are associated with the apoptosis regulation.

To identify new miRNAs modulating the expression of *OLR1* and its splice isoforms, we performed an *in silico* analysis searching for miRNA putative binding sites using popular miRNA target prediction algorithms (TargetScan and miRanda). Among the 89 putative miRNA binding sites identified, we functionally analysed and characterized the putative binding site for hsa‐miR‐24. In fact, the miR‐24 binding site, located in the 3′UTR of *OLR1*, contains a known SNP, rs1050286. Dual luciferase reporter assays showed that miR‐24 inhibited the expression of *OLR1* by binding to the 3′UTR and that the inhibitory role of miR‐24 was impacted by rs1050286 SNP.

In addition, the functional relevance of miR‐24 in regulating physiologically *OLR1* expression was established by miR‐24 overexpression studies in human cell lines heterozygous (A/G; *i.e*. HeLa) and homozygous (A/A; *i.e*. HepG2) for rs1050286 SNP. As expected, HeLa cells (A/G) showed a significant down‐regulation of *OLR1* expression both at RNA and at protein level compared to HepG2 (A/A); moreover, the overexpression of miR‐24 in HeLa cells resulted in a decrement in cell proliferation rate.

Our results demonstrate that *OLR1* is a new target of miR‐24 and that a genetic SNP (rs1050286) may disrupt miR‐24 binding site modulating *OLR1* expression level. On this basis, we postulated that *OLR1* rs1050286 SNP might contribute to modify *OLR1* susceptibility to AMI and CAD.

Even if these data may be validated by additional studies, they suggest that *OLR1* rs1050286 SNP screening could help to stratify patient risk.

Materials and methods {#jcmm12716-sec-0002}
=====================

miRNA putative binding sites *in silico* analysis {#jcmm12716-sec-0003}
-------------------------------------------------

*In silico* analysis were performed on the coding sequence and 3′UTR of *OLR1* gene using TargetScan v6.0 (<http://www.targetscan.org/>) and miRanda (<http://www.microrna.org/>) software. All algorithms were run with default parameters. TargetScan predictions were evaluated on genomic multiple alignments of human, mouse, rat, cow, dog and chicken, imposing conservation in at least five species. The TargetScan context component of the score was ignored for the predictions in the coding sequence.

Luciferase reporter assays {#jcmm12716-sec-0004}
--------------------------

The 3′UTR of *OLR1* containing the putative miR‐24 binding site (G) and the 'naturally' mutated site (A) were amplified from genomic GM06991 and GM07053B clones, respectively, and the PCR products were XhoI/NotI digested and subcloned in psiCHECK‐2 vector immediately downstream of the *Renilla Luciferase* gene. The *Firefly Luciferase* gene reporter was used as control for transfection efficiency. pEFDEST51 premiR‐24‐2 vector was used to overexpress miR‐24 [11](#jcmm12716-bib-0011){ref-type="ref"}. About 2 × 10^6^ cells have been plated in a 60‐mm Petri dish and transfected with a total of 5 μg of DNA (for the cotransfection, we used 2.5 μg of each plasmid) using *Lipofectamine 2000* (Invitrogen, Waltham, MA, USA). After 24 hrs, a luciferase assay was conducted using Dual Glo^®^ Luciferase Assay (Promega Fitchburg, WI, USA) according to the manufacturer\'s instructions.

OLR1 SNP rs1050286 genotyping {#jcmm12716-sec-0005}
-----------------------------

Genomic DNA was extracted following the Flexigene Kit protocol (Qiagen, Hilden, Germany). A TaqMan^®^ Genotyping Assay protocol (C_7433809_30; Life Technologies, Waltham, MA, USA) was used to analyse rs1050286 SNP in HeLa and HepG2 cell lines.

Cell culture and miRNA overexpression {#jcmm12716-sec-0006}
-------------------------------------

HeLa and HepG2 cell lines (ATCC) were cultured in complete medium DMEM supplemented with 10% Fetal Bovine Serum (FBS), 1× L‐glutamine, 1× Fungizone at 37°C and 5% CO~2~. Cells were seeded in triplicate at a 25,000 cell/cm^2^ density and grown in complete culture medium. Both cell lines were transiently transfected by using Calcium Phosphate Transfection Kit (Invitrogen) with 5 μg of pEFDEST51 premiR‐24‐2 vector and pEGFPN‐1 as control. Cells were harvested 48 and 72 hrs after transfection and suspended in 1 ml of Trizol (Ambion Foster City, CA, USA) (until RNA extraction) for qRT‐PCR assay and fixed in buffered formalin for immunocytochemistry.

Quantitative real time PCR {#jcmm12716-sec-0007}
--------------------------

Total RNA from transfected cells was treated with DNAse (2 U/μl; Ambion) and then retrotranscribed by using 'High Capacity cDNA Reverse Transcription Kit' (Applied Biosystems, Waltham, MA, USA). A qRT‐PCR (SYBR Green assay Applied Biosystems) assay was performed with different primers pairs, designed using the software Primer Blast, specific for each *OLR1* isoforms: OLR1 (F: *5′‐GCACAGCTGATCTGGACTTCAT‐3′*, R: *5′‐CCCCATCCAGAATGGAAAACT‐3′*), LOXIN (F: *5′‐AAAAGAGCCAAGAGAAGTGCTTGT‐3′*, R: *5′‐TCTAAATCAGATCAGCTGTGC‐3′*) and OLR1D4 (F: *5′‐TTGTTCAGGACTTCATCCAGC‐3′*, R: *5′‐TCGGACTCTAAATAAGTGGGG‐3′*). RPL37A and β‐actin genes were used for data normalization.

Western Blot analysis {#jcmm12716-sec-0008}
---------------------

Standard protein extraction was performed with RIPA lysis buffer. Denatured protein extracts (35 μg) were loaded on a 10% SDS‐PAGE. Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Hybond‐P; Amersham‐Pharmacia Biotech, GE Healthcare Life Sciences, Amersham Place, Little Chalfont, Buckinghamshire, UK). Membranes were stained with Ponceau S dye, to check for equal loading and homogeneous transfer and incubated for 1 hr at RT with 3% skim milk (Difco Lab., Detroit, MI, USA) and 0.5% Tween 20 (USB, Cleveland, OH, USA). The membrane was incubated with anti‐LOX‐1 rabbit policlonal (Abcam, Cambridge, UK) and anti‐β‐actin mouse IgG1 monoclonal antibody (Sigma‐Aldrich, Saint Louis, MO, USA). Horseradish peroxidase‐conjugated antibodies were used as secondary antibodies. Signals were detected by the SuperSignal‐detection method (Thermo Scientific, Waltham, MA, USA) and quantified by densitometry (GeneGnome; SynGene, Bangalore, Karnataka, India) after normalization for β‐actin gene product. All the experiments were repeated three times and gave similar results.

Immunocytochemistry {#jcmm12716-sec-0009}
-------------------

An anti‐LOX‐1 antibody (R&D, Minneapolis, MN, USA) was used to evaluate LOX‐1 expression. To assess the background staining, a negative control was carried out without addition of primary antibody. Secondary antibody (Biotinylated goat anti‐rabbit IgG) and following reagents (HRP‐conjugated streptavidin) were added. After washing, slides were incubated with diaminobenzidine and counterstained with haematoxylin.

Proliferation assay {#jcmm12716-sec-0010}
-------------------

Transfected cells, seeded in triplicate, at a density of 6 × 10^3^ cells/cm^2^, were counted after 24, 48, 72 and 96 hrs. Trypan blue staining was performed to evaluate cell death percentage. The cell suspension was transferred to a haemocytometer for cell counting.

Statistical analysis {#jcmm12716-sec-0011}
--------------------

Each analysis was performed in triplicate and data are expressed as mean values ± SD. Student\'s *t*‐test was used to compare two groups. A *P* ≤ 0.05 was considered to be significant.

Results {#jcmm12716-sec-0012}
=======

An *in silico* analysis using miRanda and TargetScan programs was conducted on the entire coding sequence and 3′UTR of *OLR1* and its splice isoforms to identify new miRNAs binding sites. A total of 89 miRNA putative binding sites (Table [1](#jcmm12716-tbl-0001){ref-type="table-wrap"}) potentially interacting with *OLR1* were identified. To find known SNPs that could modulate miRNA/*OLR1* gene pairing we analysed them in the miR‐SNP database (<http://www.bioguo.org/miRNASNP/>). Twenty‐three miRNAs presented SNPs in the binding region (Table [1](#jcmm12716-tbl-0001){ref-type="table-wrap"}, in bold).

###### 

List of the 89 putative miRNAs identified on coding and 3′UTR sequences of *OLR1*. The start and end position of each seed region are indicated. In bold are shown the 23 miRNAs containing a known SNP in the seed region

  miRNAs                OLR1 (NM_002543)                           
  --------------------- ------------------ ---------- ------------ ---------
  **hsa‐miR‐298**       **35**             **42**     **−0.357**   **145**
  **hsa‐miR‐3158‐5p**   ***37***           **44**     **−0.373**   **143**
  **hsa‐miR‐4274**      **77**             **83**     **−0.23**    **142**
  hsa‐miR‐4693‐3p       85                 91         −0.283       155
  hsa‐miR‐767‐5p        274                280        −0.23        159
  hsa‐miR‐3065‐3p       276                282        −0.233       155
  **hsa‐miR‐4266**      **309**            **316**    **−0.366**   **142**
  **hsa‐miR‐1258**      **311**            **318**    **−0.287**   **153**
  hsa‐miR‐3152‐3p       313                320        −0.25        142
  **hsa‐miR‐581**       **316**            **323**    **−0.279**   **149**
  hsa‐miR‐4464          329                336        −0.237       NA
  hsa‐miR‐4299          339                346        −0.361       142
  hsa‐miR‐345           403                410        −0.325       155
  hsa‐miR‐615‐3p        442                448        −0.265       NA
  hsa‐miR‐876‐5p        459                466        −0.257       147
  hsa‐miR‐3167          459                466        −0.278       140
  hsa‐miR‐4456          486                493        −0.439       140
  hsa‐miR‐620           500                507        −0.316       147
  hsa‐miR‐1270          500                507        −0.327       NA
  hsa‐miR‐432           502                509        −0.4         147
  hsa‐miR‐4754          545                552        −0.569       150
  hsa‐miR‐194           576                582        −0.246       140
  **hsa‐miR‐4642**      **640**            **647**    **−0.336**   **140**
  hsa‐miR‐198           675                681        −0.233       NA
  **hsa‐miR‐1287**      **687**            **692**    **−0.356**   **147**
  hsa‐miR‐3151          786                792        −0.339       150
  **hsa‐miR‐3917**      **802**            **808**    **−0.295**   **157**
  hsa‐miR‐3192          816                823        −0.344       151
  **hsa‐miR‐4268**      **857**            **863**    **−0.233**   **NA**
  hsa‐miR‐718           871                877        −0.242       NA
  hsa‐miR‐3614‐3p       941                947        −0.256       168
  hsa‐miR‐520a‐5p       946                953        −0.308       140
  hsa‐miR‐525‐5p        946                953        −0.318       146
  hsa‐miR‐96            1012               1019       −0.315       141
  hsa‐miR‐1271          1012               1019       −0.336       NA
  hsa‐miR‐4674          1025               1031       −0.264       140
  hsa‐miR‐378g          1026               1033       −0.384       141
  hsa‐miR‐1184          1051               1058       −0.35        NA
  **hsa‐miR‐544**       **1066**           **1073**   **−0.244**   **NA**
  hsa‐miR‐4755‐3p       1088               1095       −0.446       150
  hsa‐miR‐1302          1147               1154       −0.364       146
  hsa‐miR‐4298          1147               1154       −0.385       157
  **hsa‐miR‐1207‐5p**   **1159**           **1166**   **−0.474**   **172**
  hsa‐miR‐4763‐3p       1159               1166       −0.421       156
  **hsa‐miR‐498**       **1217**           **1224**   **−0.281**   **NA**
  hsa‐miR‐1248          1376               1383       −0.238       NA
  hsa‐miR‐4757‐5p       1385               1392       −0.403       151
  hsa‐miR‐140‐3p        1455               1461       −0.262       161
  hsa‐miR‐4451          1473               1480       −0.382       154
  hsa‐miR‐3120‐5p       1489               1496       −0.267       161
  hsa‐miR‐3120‐5p       1493               1500       −0.3         161
  hsa‐miR‐3120‐5p       1497               1505       −0.312       161
  hsa‐miR‐4286          1539               1546       −0.375       140
  hsa‐miR‐4674          1545               1552       −0.378       NA
  hsa‐miR‐635           1547               1554       −0.433       143
  hsa‐miR‐4752          1592               1599       −0.326       143
  hsa‐miR‐4795‐5p       1607               1613       −0.234       152
  **hsa‐miR‐4650‐3p**   **1644**           **1651**   **−0.379**   **NA**
  **hsa‐miR‐3909**      **1651**           **1658**   **−0.364**   **142**
  **hsa‐miR‐3611**      **1676**           **1683**   **−0.284**   **NA**
  hsa‐miR‐3153          1736               1742       −0.246       NA
  hsa‐miR‐1253          1770               1777       −0.272       150
  hsa‐miR‐567           1806               1813       −0.242       140
  hsa‐miR‐297           1807               1814       −0.286       144
  hsa‐miR‐643           1809               1816       −0.23        NA
  hsa‐miR‐4658          1831               1838       −0.337       140
  **hsa‐miR‐4777‐5p**   **1838**           **1845**   **−0.266**   **NA**
  hsa‐miR‐4481          1936               1942       −0.265       146
  hsa‐miR‐4745‐5p       1936               1942       −0.265       140
  **hsa‐miR‐24**        **1942**           **1964**   **−0.267**   **141**
  **hsa‐miR‐516a‐3p**   **1965**           **1971**   **−0.265**   **157**
  hsa‐miR‐3944‐5p       1983               1990       −0.503       151
  hsa‐miR‐3074‐5p       1998               2004       −0.254       157
  **hsa‐miR‐4639‐3p**   **2172**           **2179**   **−0.419**   **141**
  hsa‐miR‐3201          2181               2188       −0.319       140
  hsa‐miR‐4791          2181               2188       −0.351       154
  hsa‐miR‐3134          2184               2191       −0.356       NA
  hsa‐miR‐4459          2214               2221       −0.33        144
  **hsa‐miR‐4667‐5p**   **2229**           **2236**   **−0.376**   **158**
  **hsa‐miR‐4700‐5p**   **2229**           **2236**   **−0.366**   **NA**
  **hsa‐miR‐876‐3p**    **2238**           **2245**   **−0.371**   **147**
  hsa‐miR‐518a‐5p       2327               2333       −0.237       NA
  hsa‐miR‐527           2327               2333       −0.237       NA
  hsa‐miR‐4534          2357               2363       −0.253       141
  hsa‐miR‐4272          2395               2402       −0.253       142
  hsa‐miR‐4506          2434               2440       −0.283       146
  hsa‐miR‐4733‐5p       2473               2480       −0.393       161
  hsa‐miR‐646           2491               2497       −0.283       143
  hsa‐miR‐578           2512               2518       −0.261       NA
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Among them, rs1050286 SNP (G\>A), mapping in the 3′UTR of the *OLR1* gene, is located within the seed‐binding region for hsa‐miR‐24 (Fig. [1](#jcmm12716-fig-0001){ref-type="fig"}A and B).

![Effect of miR‐24 overexpression on *OLR1* 3′ UTR luciferase activity. (**A**) A graphic representation of miR‐24 binding site on *OLR1* 3′UTR. The miR‐24 seed region is underlined. The position of SNP rs 1050286 is shown. (**B**) Prediction scores of the interaction between *OLR1* and miR‐24 by TargetScan and miRanda software. (**C**) Luciferase assay results. Data were normalized to Firefly luciferase activity and to cells transfected with control vectors (empty psiCHECK‐2 or 3′UTR(G) alone or 3′UTR(A) alone). Error bars represent standard deviation of technical repeat experiments (*n* = 3).](JCMM-20-181-g001){#jcmm12716-fig-0001}

To test the interaction between *OLR1* 3′UTR and miR‐24, we performed an *in vitro* luciferase assay. HeLa cells transfected with a plasmid expressing *OLR1* 3′UTR with a conserved hsa‐miR‐24 seed region (*i.e*. containing G nucleotide) showed a significant (*P* \< 0.0005) reduction in luciferase level; on the contrary, luciferase level did not change when the same cells were transfected with a plasmid expressing mutated 3′UTR (containing A nucleotide) (Fig. [1](#jcmm12716-fig-0001){ref-type="fig"}C). These results confirm that *OLR1* is a bona fide miR‐24 target. Moreover, this functional analysis proved that the rs1050286 G‐allele leads to a significant lower luciferase activity (*P* \< 0.0005), compared with the A allele, thus demonstrating that *in vitro* interaction among miR‐24 and *OLR1* is impaired by rs1050286 SNP.

To confirm miR‐24/*OLR1* binding, we analysed *OLR1* and its splice isoform expression (mRNA and protein) in two human cell lines with different genotype (A/G *versus* A/A) both at 48 hrs and at 72 hrs after miR‐24 transfection. Although 48 hrs after transfection we did not observe significant changes in *OLR1* mRNA and protein levels (data not shown), 72 hrs post transfection, HeLa cells (A/G) overexpressing miR‐24 showed a significant *OLR1* (and its splice isoforms) mRNA decrease compared to cells transfected with control vector (Fig. [2](#jcmm12716-fig-0002){ref-type="fig"}A). Accordingly, LOX‐1 protein level decreased to about 65% in HeLa overexpressing miR‐24 (Fig. [2](#jcmm12716-fig-0002){ref-type="fig"}B). LOX‐1 down‐regulation by miR‐24 was also evident using Immunocytochemistry experiments (Fig. [2](#jcmm12716-fig-0002){ref-type="fig"}C--F). On the contrary, *OLR1* and its splice isoform expression level (both mRNA and protein) did not change in HepG2 (A/A) after miR‐24 overexpression (Fig. [2](#jcmm12716-fig-0002){ref-type="fig"}A, B, G--J).

![LOX‐1 expression in HeLa and HepG2 cells is modulated by miR‐24 overexpression and rs1050286 SNP. (**A**) qRT‐PCR results. (**B**) Western blot analysis. Bar graphs show the ratio of LOX‐1 to β‐actin. The experiments were repeated three times and the data show the representative results. (**C--K**) Immunocytochemistry results. (**C, E, G, I**) Control plasmid; (**D, F, H, J**) miR‐24 transfected cells. (**C, D, G, H**) 20× magnification; (**E, F, I, J**) 40× magnification. (**K**) HeLa and HepG2 proliferation assay.](JCMM-20-181-g002){#jcmm12716-fig-0002}

Interestingly, 96 hrs after seeding the overexpression of miR‐24 inhibits cell growth in HeLa cells with respect to the same cell line transfected with the empty plasmid, whereas cell growth did not change in HepG2 cells overexpressing miR‐24 compared to the same cells transfected with empty vector (*P* \< 0.01, Fig. [2](#jcmm12716-fig-0002){ref-type="fig"}K).

Discussion {#jcmm12716-sec-0013}
==========

LOX‐1, encoded by the *OLR1* gene, is the major endothelial receptor for ox‐LDL and plays a fundamental role in the pathogenesis of atherosclerosis [1](#jcmm12716-bib-0001){ref-type="ref"}, [2](#jcmm12716-bib-0002){ref-type="ref"}, [4](#jcmm12716-bib-0004){ref-type="ref"}. Moreover, it has been demonstrated that normal LOX‐1 activity is essential for maintaining the structural integrity of tissues; in fact, an increased activity of LOX‐1 is associated with cancer cell invasion [12](#jcmm12716-bib-0012){ref-type="ref"}.

*OLR1* is a spliced gene and its alternative splicing is regulated by six intronic SNPs spanning from intron 4 to 3′UTR; these SNPs are in linkage disequilibrium and related to a higher risk of developing AMI [3](#jcmm12716-bib-0003){ref-type="ref"}, [4](#jcmm12716-bib-0004){ref-type="ref"}. In fact, a specific haplotype (*5′‐CTGGTT‐3′*) correlates with a OLR1/LOXIN ratio 33% higher than those identified in individuals carrying another haplotype (*5′‐GCAAGC‐3*′), and the *5′‐CTGGTT‐3′* haplotype was significantly associated with CAD and myocardial infarction [3](#jcmm12716-bib-0003){ref-type="ref"}, [5](#jcmm12716-bib-0005){ref-type="ref"}.

Based on this and other data, LOX‐1 is generally considered a promising therapeutic target for both atherosclerosis and cancer [13](#jcmm12716-bib-0013){ref-type="ref"}.

Therefore, to identify molecular factors that may regulate the *OLR1* expression, we performed an *in silico* analysis on the coding sequence and 3′UTR of *OLR*1 gene to search putative miRNA binding sites. As functional polymorphisms in 3′UTRs of several genes have been reported to be associated with diseases by affecting gene expression, we searched for SNPs, in the coding sequence and in the UTRs of *OLR1*, which map in the identified miRNA putative binding sites. We found a putative hsa‐miR‐24 binding site that is 'naturally' mutated, inside its seed region, by a common SNP (rs1050286) (Fig. [1](#jcmm12716-fig-0001){ref-type="fig"}). In fact, in the European population the frequency of the G allele, that results in a conserved miR‐24 seed region, is 0.483, whereas the A allele has a frequency of 0.517. However, in black/African‐Americans and in East Asians the G allele has a frequency of 0.233 (dbSNP[,]{.ul} <http://www.ncbi.nlm.nih.gov/>).

*In vitro* luciferase assay and overexpression studies demonstrate an interaction among miR‐24 and *OLR1* and also that rs1050286 alters the binding affinity between miR‐24 and its 3′UTR, thus reducing the suppression of *OLR1* expression.

miR‐24 is commonly considered as a multifunctional cardio‐miR that plays good and bad roles in heart; in fact, it protects cardiomyocytes from apoptosis and reduces cardiac fibrosis, but inhibits angiogenesis and deteriorates heart failure [14](#jcmm12716-bib-0014){ref-type="ref"}. Moreover, miR‐24 is up‐regulated in the chronic phase after myocardial infarction and promotes hypertrophic growth of cardiomyocytes in mouse model experiments and the cardiac overexpression of miR‐24 resulted in scar size reduction and heart function improvement [15](#jcmm12716-bib-0015){ref-type="ref"}. Our findings suggest that the rs1050286 SNP in the *OLR1* 3′UTR, by disrupting the regulatory role of miR‐24 on *OLR1* expression, may contribute to the occurrence of atherosclerosis. Moreover, these results highlight the importance of genotype‐dependent differential microRNA regulation in relation to human disease risk.

Finally, these evidence suggest that *OLR1* could be a new therapeutic target for miR‐24 and represent a starting point for the development of possible therapeutic strategies against diseases related to *OLR1* overexpression.
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